Cannabis and addiction
Browse the latest research linking medical marijuana / medicinal cannabis and addiction.
Cannabis and cannabinoids and the treatment of addiction disorders
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
CBD opioid,heroin,addiction in humans via placebo trial Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial May 2019
Ingestion Method: oral 400-800mg
Positive  Acute CBD administration, in contrast to placebo, significantly reduced both craving and anxiety induced by the presentation of salient drug cues compared with neutral cues. CBD also showed significant protracted effects on these measures 7 days after the final short-term (3-day) CBD exposure. In addition, CBD reduced the drug cue-induced physiological measures of heart rate and salivary cortisol levels. There were no significant effects on cognition, and there were no serious adverse effects.
THC addiction,opioid in rats Low dose combination of morphine and delta-9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors Oct 2008
Administration of THC attenuated cannabinoid CB1 receptor-stimulated G-protein activity in both periaqueductal gray and spinal cord, and administration of morphine decreased mu opioid receptor-stimulated [35S]GTPgS binding in spinal cord or periaqueductal gray, depending on route of administration
cannabinoids pain,addiction,obesity via article Cannabinoids: Friend or Foe? Jun 2016
These are interesting time for cannabinoid research and clinical application; much more needs to be done to translate the potential of cannabinoid drugs to medicinal use and to identify the conditions that could benefit from this class of drugs. There is as yet untapped potential in the areas of pain and addiction, obesity, metabolic syndrome and epilepsy
cannabis addiction,opioid via review Emerging Evidence for Cannabis' Role in Opioid Use Disorder Sept 2018
The compelling nature of these data and the relative safety profile of cannabis warrant further exploration of cannabis as an adjunct or alternative treatment for OUD.
CBD,THC addiction,anti-psychotic via review The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. Jul 2019
CBD and THC mixtures showed positive effects in reducing short-term withdrawal and craving in cannabis use disorders. Studies on schizophrenia and comorbid substance use are lacking. Future studies should focus on the effects of CBD on psychotic disorders in different stages of illness, together with the effects on comorbid substance use.
CBD addiction,opioid,methamphetamine via review Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms Jun 2019
In the present work, the authors describe the scarce preclinical and human research about the actions of CBD on the effects of stimulant drugs, mainly cocaine and methamphetamine (METH). Additionally, the possible mechanisms underlying the therapeutic potential of CBD on stimulant use disorders are reviewed.
THC addiction,opioid in rats via experiment Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC Jan 1975
Abstinence scores in animals pretreated acutely with 10 mg/kg delta 9-THC one hour before naloxone were significantly less than those of a vehicle control group, and wet shakes and gastrointestinal signs of abstinence were blocked. These results extend previous observations of morphine abstinence attenuating properties of delta 9-THC to effects on animals dependent on methadone.
THC addiction,opioid via review Endocannabinoid system and opioid addiction: behavioural aspects. Jun 2005
The current review examines progresses in the past few years in the elucidation of cannabinoid-opioid interactions in drug abuse and dependence, focusing on recent findings from behavioural studies using different animal models of addiction. Specifically, here we review data on the behavioural aspects (i.e., drug abuse, dependence, tolerance, sensitization, relapse and drug vulnerability) of the specific, often reciprocal, cross-talk between cannabinoids and opioids with particular reference to the role of the endocannabinoid system in opioid addiction.
CBD addiction,nicotine in humans via placebo trial (n=24) Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Sept 2013
Positive  Over the treatment week, placebo treated smokers showed no differences in number of cigarettes smoked. In contrast, those treated with CBD significantly reduced the number of cigarettes smoked by ~40% during treatment. Results also indicated some maintenance of this effect at follow-up.
cannabis addiction,opioid in humans via study (n=820) High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis Dec 2018
Among people who use illicit drugs initiating opioid agonist treatment in Vancouver, at least daily cannabis use was associated with approximately 21% greater odds of retention in treatment compared with less than daily consumption.
CBD addiction,methamphetamine in rats via experiment (n=32) Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. Dec 2018
Ingestion Method: 80mg/kg
Positive  Cannabidiol (80 mg/kg, but not 40 mg/kg, or 20 mg/kg) reduced the motivation to self-administer methamphetamine and attenuated methamphetamine-primed relapse to methamphetamine-seeking behavior after extinction.
THCV addiction,nicotine in rats via experiment Tetrahydrocannabivarin has potent anti-nicotine effects in multiple rodent models of nicotine dependence. Aug 2019
We conclude that delta-8 -THCV may have therapeutic potential for the treatment of nicotine dependence. We also suggest that tetrahydrocannabivarins should be tested for possible anti-addiction efficacy in a broader range of preclinical animal models, against other addictive drugs, and eventually in humans.
CBD addiction in rats via experiment Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-TH1A and TRPV1 receptor mechanisms Aug 2019
Ingestion Method: 10-40 mg/kg
Action Pathway: CB2
CBD dose-dependently inhibited cocaine self-administration and shifted cocaine dose-response curve downward under FR reinforcement. CBD lowered break-point level for cocaine self-administration under PR reinforcement.
CBD addiction in rats via experiment Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-TH1A and TRPV1 receptor mechanisms Aug 2019
Ingestion Method: 10-40mg/kg
Action Pathway: CB2,5-HT1A,TRPV1
Systemic administration (10-40 mg/kg) of CBD dose-dependently inhibited cocaine self-administration, shifted cocaine dose-response curve downward, and lowered break-point for cocaine self-administration under a progressive-ratio schedule of reinforcement.